Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy
Executive Summary
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
You may also be interested in...
2021 Marked New Era Of Domestic Collaboration in China
Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.
Chinese Firms Look Inward To Access Innovation
Two recent licensing deals involving Chinese firms underscore the record level of agreements being inked between innovative domestic biotechs and generic drug makers, at a time when corporate valuations and geopolitical tensions have made cross-border transactions harder to grab.
Aurobindo And MSN Labs Join Others In Settling On Allergan’s Fetzima
Two more ANDA companies have reached settlement agreements with AbbVie’s Allergan subsidiary and partner Pierre Fabre Medicament over proposed generic versions of the Fetzima serotonin and norepinephrine reuptake inhibitor.